A novel synthesis of 3-cyano-2(1H)-pyridinethiones, chromene-3-carbothioamide and chromeno[3,4-c]pyridines were obtained through interaction of N-aryl cyanothioacetamide derivatives with some electrophilic reagents. Most of the target compounds were then evaluated for their antimicrobial and antifungal activities.
Introduction
3-Cyano-2(1H)-pyridinethiones [1, 2] and their related compounds were found to be very reactive substances for the synthesis of many different heterocyclic systems which exhibited biological activities such as antibacterial, pesticidal, antifungal, acaricidal and neurotropic activities [3] [4] [5] [6] [7] [8] [9] [10] . Also, the 3-Cyano-pyridine-2(1H)-thiones compounds have gained considerable interest due to their importance as intermediates for the synthesis of the biologically active deazafolic acid and deaza amino protein ring system [11, 12] . Thus, the synthesis of pyridines and their analogs has attracted much attention. Therefore, the development of a simple, one-pot, and directed synthetic route, which provides diverse of 3-cyano-pyridinethione compounds, is strongly desired for this important class of heterocycles. Also, chromene derivatives are widely used for production of highly effective fluorescent dyes for synthetic fiber and daylight fluorescent pigments [13] [14] [15] . They also play a vital role in electrophotographic and electroluminescent devices [16] .
As a part of our program directed for the development of a new, simple and efficient procedure for the synthesis of biologically active heterocyclic nitrogenous compounds utilizing readily available intermediates [17] [18] [19] [20] [21] [22] [23] [24] , we have investigated the reaction of N-aryl cyanothioacetamide derivatives 1a,b with some electrophilic reagents. The investigation has resulted in the development of novel procedure for the synthesis of 3-cyano-2(1H)-pyridinethiones and their fused derivatives. These compounds seem promising for further chemical transformation and biological evaluation studies.
Methods
All melting points are uncorrected. IR spectra (KBr) were measured on Shimadzu 440 spectrometer, 1 HNMR spectra were obtained in DMSO-d 6 on a Varian Gemini 200 MHz spectrometer using TMS as internal standard; chemical shifts are reported as (ppm). Mass spectra were obtained on GCMS\QP 1000 Ex mass spectrometer at 70 ev. Elemental analyses were carried out at the Microanalytical Center, Faculty of Science (Cairo University, Egypt). Microbiology screening was carried out in Botany Department, Faculty of Science, Al-Azhar University.
4,6-Diamino-1-(4-chlorophenyl)-2-thioxo-1,2-dihydropyridine-3-carbonitrile (3).
A mixture of 1 (0.01 mole), malononitrile (0.01 mole) and a few drops of piperidine was refluxed for 2h in an oil bath at 160°C, then allowed to cool. The solid product was collected and recrystallized from dioxane as yellow crystals to give (3). 1-p-Tolyl-4,6-dimethyl-2-thioxo-1,2-dihydropyridine-3-carbonitrile (5). Equimolar amounts of 1a (0.01 mole) and acetylacetone (0.01 mole) with a few drops of piperidine in an oil bath were refluxed for 1h at 160°C, then allowed to cool. The solid product was collected and recrystallized from acetic acid as brown crystals to give 5. 1-p-Chlorophenyl-6-methyl-4-(2-methyl-4-oxopent-1-enyl)-2-thioxo-1,2-dihy-dropyridine-3-carbonitrile (7). A mixture of 1a (0.01 mole) and acetyl acetone (0.02 mole) with a few drops of piperidine in an oil bath were refluxed for 2h at 160°C, then allowed to cool. The solid product was collected and recrystallized from acetic acid as brown crystals to give 7. 6-Amino-4-(2-chlorophenyl)-2-thioxo-1-p-tolyl-1,2,3,4-tetrahydropyridine-3,5-dicarbonitrile (11); 6-amino-1,4-bis(4-chlorophenyl)-2-thioxo-1,2-dihydropyridine-3,5-dicarbonitrile (13). General procedure: A mixture of 1 (0.01 mole) and the appropriate arylidenemalononitrile (0.01 mole) in ethanol (30 ml) was treated with piperidine (0.5 ml) and the reaction mixture was refluxed for 3h. The solid product which produced on heating was filtered and recrystallized from the proper solvent to give 11 and 13 respectively. 
Compound (11

2-Imino-3-N-(4-chlorophenyl)-thioxocarboxamido-2H-chromene (15), N-(4-chloro-phenyl)-3-imino-3H-benzo[f]chromene-2-carbothioamide (17). General procedure:
A mixture of compound 1b (0.01 mole), appropriate aldehyde (salicylaldehyde or 2-hydroxynaphthaldehyde; 0.01 mole) and ammonium acetate (0.01 mole) in ethanol (30 ml) was refluxed for 1h. The solid product which produced on heating was collected and recrystallized to furnish 15 and 17. 
Compound (15).This
N-(4-Substituted-phenyl)-2-oxo-2H-chromene-3-carbothioamide (16a,b), N-(4-chlorophenyl)-3-oxo-3H-benzo[f]chromene-2-carbothioamide (18). General procedure:
Method A: A mixture of compound 1 (0.01 mole), appropriate o-hydroxyaldehyde (salicylaldehyde or 2-hydroxynaphthaldehyde; 0.01 mole) and sodium acetate (0.01 mole) was refluxed in acetic anhydride (30 ml) for 1h. The resulting solid was filtered off and recrystallized from the suitable solvent.
Method B: A suspension of 15 or 17 (0.01 mole) in ethanol (30 ml), hydrochloric acid (5 ml) was refluxed for 1h, then cooled and the solid product was filtered off and recrystallized from the proper solvent. -3-(4-chlorophenyl)-5-imino-4-thioxo-4,5-dihydro-3H-chromeno[3,4-c]-pyridine-1-carbonitrile (20), 3-(4-chlorophneyl)-5-imino-2-oxo-4-thioxo-2,3, 4a,5, 10b-hexahydro-1H-chromeno[3,4-c]pyridine-1-carbonitrile (22)  and 5-imino-2-(4-chlorophenylamino)-3-(4-chlorophenyl)-4-thioxo-4,6-dihydro-3H-chromeno[3,4-c]-pyridine-1-carbonitrile (24) . General procedure: A mixture of 15 (0.01 mole), active methylene compounds (namely, malononitrile, ethyl cyanoacetate, 2-cyano-N-tolylthio-acetamide 1a; 0.01 mole) and a few drops of piperidine in ethanol (30 ml) was heated under reflux for 3h. The solid product which produced on heating was collected by filtration and recrystallized from the proper solvent. 
Compound (16a
2-Amino
Compound (20
2-(4-Chlorophenylamino)-5-imino-4-oxo-4,5-dihydro-3H-chromeno[3,4-c]pyridine-1-carbonitrile (27).
A mixture of 1b (0.01 mole), 2-imino-chromene-3-carboxamide 25 (0.01 mole) and a few drops of piperidine in dioxane (30 ml) was refluxed for 3h. The solid product produced on heating was collected and recrystallized from DMF as brown crystals to give 27. 
Results and Discussion
The key intermediate N-aryl cyanothioacetamide derivatives 1a,b were prepared in high yield from the thionation of N-aryl 2-cyanoacetamide derivatives with P 2 S 5 in pyridine at reflux temperature [24] . The reactivity of 1a,b toward some active methylene reagents was also investigated. Thus, cyanothioacetamide derivative1b was reacted with malononitrile (1: 1 molar ratio) in an oil bath at 160°C to yield 4, 6-diamino-2-pyridinethione derivative 3. The infrared spectrum of compound 3 revealed absorption bands at 3314, 3182 (NH 2 ), 2204 cm -1 (C≡N).
1 HNMR spectrum of 3 showed singlet at 5.40 ppm due to pyridine-H5 with two singlets at 5.80, 6.55 ppm for 2NH 2 . Also, its mass spectrum showed a molecular ion peak at m/z 276 (3.90%).
The formation of 3 is assumed to proceed via the nucleophilic addition of 1 to the cyano function of malononitrile to form the acyclic adduct 2 followed by intramolecular cyclization. Also, cyclocondensation of 1a with acetylacetone under reflux conditions furnished 4,6-dimethyl-2-pyridinethione derivatives 5 via intramolecular cyclization of non-isolable intermediate 4 followed by dehydration, scheme 1. 1 HNMR spectrum of 5 showed three signals at 2.10, 2.25, and 2.40 ppm for three CH 3 with singlet at 6.30 for pyridine-H5. The mass spectrum of 5 was compatible with the molecular formula C 15 H 14 N 2 S (M = 254). While cyclocondensation of 1b with acetylacetone under the same condition, two moles of acetylacetone were consumed and 2-pyridine-thione derivative 7 was obtained. The infrared spectrum of 7 revealed absorption bands at 2217, 1653 and 1305 cm -1 for nitrile, carbonyl and thiocarbonyl function groups, respectively. 1 HNMR spectrum of 7 showed signals at δ = 1.97, 2.05 and 2.42 ppm for three methyl groups with singlet at 3.00 ppm for methylene group and two singlets at 6.45, and 6.97 ppm due to olefinic-H and pyridine-H, in addition to aromatic protons. Furthermore, the structure of compound 7 was supported by 
Scheme 1
As a part of this research, the reaction of N-aryl cyanothioacetamide derivatives with unsaturated nitriles was also investigated. Thus, when equimolecular amounts of N-aryl cyanothioacetamides 1a,b and tetracyanoethylene8a were reacted in the presence of a catalytic amount of triethylamine, pyridinethione of type 10 was obtained. The structures of 10a,b were confirmed on the basis of elemental analysis and spectral data. The infrared spectrum of 10a showed absorption bands at 3314, 3182 (NH 2 ), 2190, 2204 cm -1 (C≡N).
1
HNMR spectrum (DMSO-d 6 ) of 10a revealed singlet at δ 2.30 corresponding CH 3 in addition to the presence of aromatic and NH 2 protons. Furthermore, the mass spectrum supported the structure of 10a and exhibited a molecular ion peak at m/z 291 (3.50%). The formation of 10 was assumed to proceed via Michael addition of the active methylene of 1 to the activated double bond of tetracyanoethylene 8a to form the non-isolable intermediate 9 followed by intramolecular cyclization and loss of hydrogen cyanide, Scheme 2. In addition, it has been found that compound 1a was reacted with o-chlorocinnamonitrile 8b to yield 1 : 1 Michael adduct 9 as intermediate which underwent cyclization to afford the dihydropyridinethione derivative 11. The infrared spectrum showed bands at 3448, 3328 (NH 2 ), and 2189 cm -1 (C≡N). Also,
HNMR spectrum exhibited signals at δ: 2.14 (s, 3H, CH 3 ), 4.12, 4.39 (2d, 2H, pyridine H3, H4; J=12Hz). On the other hand, reaction of cyanothioacetamide derivative 1b with p-chlorocinnamonitrile 8c afforded pyridinethione derivative 13 through intermediate 12.
The mass spectrum of compound 13 showed a molecular ion peak at m/z 397 (34.77%) which is in agreement with its molecular formula C 19 H 10 Cl 2 N 3 S. It seems that 13 was formed via the formation of Michael adduct 9 which underwent cyclization and oxidation through intermediate 12. Chemical Sciences Journal, Volume 2011: CSJ-36
Finally, treatment of cyanothioacetamide derivative 1b with 2-iminochromene-3-carboxamide 25 [25] in the presence of piperidine as catalyst afforded the chromeno [3,4-c] pyridine derivative 27, and the other possible structure 26 was excluded on the basis of analytical and spectral data, scheme 5. Infrared spectrum of 27 showed absorption bands at 3365, 3165 (NH), 2201 (C≡N) and 1676 cm -1 (C=O). 1 HNMR spectrum of 27 revealed signals at δ: 8.99 (s, 1H, NH) and 10.34 ppm (broad s, 2H, 2NH) and the mass spectrum were compatible with the molecular formula C 19 H 11 ClN 4 O 2 (M+1; 363).
Scheme 5
All the synthesized compounds were evaluated in vitro for their antibacterial activity against Escherichia coli NCTC-10418 and Bacillus subtilis NCTC-10400. Also, the antifungal activity against Candida albicans CBS-652, and Aspergillus flavus LTV.131 was evaluated using the agar-diffusion technique [26] . A 1 mg mL -1 solution in dimethylformamide (DMF) was used. The bacteria and fungi were grown on nutrient agar and Czapek's-Dox agar media, respectively. DMF as a negative control did not show inhibition zones. The agar media were inoculated with different micro-organism cultures tested. After 25 h of incubation at 30ºC for bacteria and 48 h for fungi, the diameter of inhibition zone (mm) was measured. Ampicillin (25 µg mL -1 ) and Mycostatine (30 µg mL -1 ) were used as reference drugs for anti-bacterial and antifungal activities, respectively. Most of the synthesized compounds were found to possess various antimicrobial activities towards all the microorganisms used (Table 1) . Compounds 3, 7 and 11 were found to possess highest antibacterial activity towards E. coli and Candida albicans with minimal inhibitory concentration (MIC) values <50 mg mL -1 . In addition, compounds 5, 13, 15, 18, 20 and 22 revealed high activity against E. coli, Bacillus subtilis and Candida albicans, MIC values <50 mg mL -1 . However, none of the test compounds show superior activity than the reference drugs. 
